Identification of surrogate markers for determining drug activity using proteomics
1Cancer Biology Laboratory, Research School of Biosciences, University of Kent, Canterbury, Kent CT2 7NJ, U.K. cmm@kent.ac.uk
Abstract:
In a high proportion of human carcinomas overexpression of the EGFR (epidermal growth factor receptor), a receptor tyrosine kinase, represents a potential target for cancer treatment. EGFR is induced to dimerize through ligand binding which activates the tyrosine kinase activity of the receptor. This catalyses the transfer of ATP's gamma-phosphate to hydroxyl groups of tyrosine residues on the receptor, creating binding sites that recruit downstream signalling proteins. New drugs, SMTKIs (small-molecule tyrosine kinase inhibitors), have been designed to inhibit the tyrosine kinase activity of the receptor, producing an anti-tumour effect. The development of surrogate markers to determine the drug activity of these new inhibitors would be of great benefit in drug evaluation and in the subsequent management of patient disease. This review describes current treatments of cancer using tyrosine kinase inhibitors and the use of proteomic analysis to identify possible markers of activity of these new drugs.
Insights
Overexpression of the epidermal growth factor receptor (EGFR) is common in carcinomas. This review explores small-molecule tyrosine kinase inhibitors (SMTKIs) for cancer treatment and the use of proteomic analysis to find markers of their activity.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Epidermal growth factor receptor (EGFR) overexpression is prevalent in human carcinomas, making it a significant therapeutic target.
- EGFR activation, triggered by ligand binding, initiates downstream signaling pathways crucial for cell growth and survival.
- Dysregulation of EGFR signaling contributes to cancer development and progression.
Purpose of the Study:
- To review current cancer treatments utilizing tyrosine kinase inhibitors (TKIs).
- To explore the potential of proteomic analysis in identifying surrogate markers for TKI drug activity.
- To discuss the benefits of such markers in drug evaluation and patient management.
Main Methods:
- Literature review of current TKI therapies in cancer treatment.
- Discussion of proteomic analysis techniques for biomarker discovery.
- Analysis of EGFR signaling pathways and TKI mechanisms of action.
Main Results:
- Small-molecule tyrosine kinase inhibitors (SMTKIs) are designed to inhibit EGFR's tyrosine kinase activity, yielding anti-tumor effects.
- Proteomic analysis offers a promising approach to identify novel surrogate markers for TKI efficacy.
- Effective markers can aid in optimizing TKI therapy and managing patient outcomes.
Conclusions:
- EGFR-targeted therapies, particularly SMTKIs, represent a vital strategy in cancer treatment.
- The development and validation of proteomic-based surrogate markers are crucial for advancing TKI-based cancer care.
- Identifying reliable markers will enhance drug evaluation and personalize patient treatment strategies.
More Related Videos
10:37Deep Proteome Profiling by Isobaric Labeling, Extensive Liquid Chromatography, Mass Spectrometry, and Software-assisted Quantification
Published on: November 15, 2017
08:31Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
